259 related articles for article (PubMed ID: 32835489)
1. Novel High-Drug-Loaded Amorphous Dispersion Tablets of Posaconazole;
Mudie DM; Stewart AM; Biswas N; Brodeur TJ; Shepard KB; Smith A; Morgen MM; Baumann JM; Vodak DT
Mol Pharm; 2020 Dec; 17(12):4463-4472. PubMed ID: 32835489
[TBL] [Abstract][Full Text] [Related]
2. A novel architecture for achieving high drug loading in amorphous spray dried dispersion tablets.
Mudie DM; Buchanan S; Stewart AM; Smith A; Shepard KB; Biswas N; Marshall D; Ekdahl A; Pluntze A; Craig CD; Morgen MM; Baumann JM; Vodak DT
Int J Pharm X; 2020 Dec; 2():100042. PubMed ID: 32154509
[TBL] [Abstract][Full Text] [Related]
3. Amorphous solid dispersion of nisoldipine by solvent evaporation technique: preparation, characterization, in vitro, in vivo evaluation, and scale up feasibility study.
Chavan RB; Lodagekar A; Yadav B; Shastri NR
Drug Deliv Transl Res; 2020 Aug; 10(4):903-918. PubMed ID: 32378174
[TBL] [Abstract][Full Text] [Related]
4. The influence of crushing amorphous solid dispersion dosage forms on the in-vitro dissolution kinetics.
Pas T; Verbert S; Appeltans B; Van den Mooter G
Int J Pharm; 2020 Jan; 573():118884. PubMed ID: 31786356
[TBL] [Abstract][Full Text] [Related]
5. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance.
Indulkar AS; Lou X; Zhang GGZ; Taylor LS
Mol Pharm; 2019 Mar; 16(3):1327-1339. PubMed ID: 30669846
[TBL] [Abstract][Full Text] [Related]
6. Inhomogeneous Phase Significantly Reduces Oral Bioavailability of Felodipine/PVPVA Amorphous Solid Dispersion.
Gao D; Zhu D; Zhou X; Dong S; Chen Y
Mol Pharm; 2023 Jan; 20(1):409-418. PubMed ID: 36529939
[TBL] [Abstract][Full Text] [Related]
7. Impact of Processing Methods on the Physico-chemical Properties of Posaconazole Amorphous Solid Dispersions.
He R; Lamm MS; Brunskill A; Axnanda S; Li Y
Pharm Res; 2024 Jan; 41(1):141-151. PubMed ID: 38040879
[TBL] [Abstract][Full Text] [Related]
8. Congruent Release of Drug and Polymer from Amorphous Solid Dispersions: Insights into the Role of Drug-Polymer Hydrogen Bonding, Surface Crystallization, and Glass Transition.
Saboo S; Kestur US; Flaherty DP; Taylor LS
Mol Pharm; 2020 Apr; 17(4):1261-1275. PubMed ID: 32134677
[TBL] [Abstract][Full Text] [Related]
9. Combining amorphous solid dispersions for improved kinetic solubility of posaconazole simultaneously released from soluble PVP/VA64 and an insoluble ammonio methacrylate copolymer.
Danda LJA; Batista LM; Melo VCS; Soares Sobrinho JL; Soares MFR
Eur J Pharm Sci; 2019 May; 133():79-85. PubMed ID: 30890364
[TBL] [Abstract][Full Text] [Related]
10. Combined Effects of Supersaturation Rates and Doses on the Kinetic-Solubility Profiles of Amorphous Solid Dispersions Based on Water-Insoluble Poly(2-hydroxyethyl methacrylate) Hydrogels.
Schver GCRM; Lee PI
Mol Pharm; 2018 May; 15(5):2017-2026. PubMed ID: 29601723
[TBL] [Abstract][Full Text] [Related]
11. High Bulk-Density Amorphous Dispersions to Enable Direct Compression of Reduced Tablet Size Amorphous Dosage Units.
Frank DS; Nie H; Chandra A; Coelho A; Dalton C; Dvorak H; Elkhabaz A; Fahy M; Ormes J; Parker A; Punia A; Rowe J; Schenck L; Smith D; Strotman NA; Wang M; Wareham L
J Pharm Sci; 2023 Aug; 112(8):2037-2045. PubMed ID: 36115592
[TBL] [Abstract][Full Text] [Related]
12. Impact of polymer type, ASD loading and polymer-drug ratio on ASD tablet disintegration and drug release.
Zhang W; Noland R; Chin S; Petkovic M; Zuniga R; Santarra B; Conklin B; Hou HH; Nagapudi K; Gruenhagen JA; Yehl P; Chen T
Int J Pharm; 2021 Jan; 592():120087. PubMed ID: 33189812
[TBL] [Abstract][Full Text] [Related]
13. Producing Amorphous Solid Dispersions via Co-Precipitation and Spray Drying: Impact to Physicochemical and Biopharmaceutical Properties.
Mann AKP; Schenck L; Koynov A; Rumondor ACF; Jin X; Marota M; Dalton C
J Pharm Sci; 2018 Jan; 107(1):183-191. PubMed ID: 28711592
[TBL] [Abstract][Full Text] [Related]
14. Amorphous Salts Solid Dispersions of Celecoxib: Enhanced Biopharmaceutical Performance and Physical Stability.
Mukesh S; Joshi P; Bansal AK; Kashyap MC; Mandal SK; Sathe V; Sangamwar AT
Mol Pharm; 2021 Jun; 18(6):2334-2348. PubMed ID: 34003656
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability of itraconazole in rats and rabbits after administration of tablets containing solid dispersion particles.
Yoo SD; Lee SH; Kang E; Jun H; Jung JY; Park JW; Lee KH
Drug Dev Ind Pharm; 2000 Jan; 26(1):27-34. PubMed ID: 10677807
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive evaluation of polymer types and ratios in Spray-Dried Dispersions: Compaction, Dissolution, and physical stability.
Yu D; Nie H; Hoag SW
Int J Pharm; 2024 Jan; 650():123674. PubMed ID: 38061497
[TBL] [Abstract][Full Text] [Related]
17. Effect of Counterions on Dissolution of Amorphous Solid Dispersions Studied by Surface Area Normalized Dissolution.
Chen Y; Lubach JW; Tang S; Narang AS
Mol Pharm; 2021 Sep; 18(9):3429-3438. PubMed ID: 34338529
[TBL] [Abstract][Full Text] [Related]
18. Oral bioavailability enhancement of β-lapachone, a poorly soluble fast crystallizer, by cocrystal, amorphous solid dispersion, and crystalline solid dispersion.
Liu C; Liu Z; Chen Y; Chen Z; Chen H; Pui Y; Qian F
Eur J Pharm Biopharm; 2018 Mar; 124():73-81. PubMed ID: 29305142
[TBL] [Abstract][Full Text] [Related]
19.
Jermain SV; Lowinger MB; Ellenberger DJ; Miller DA; Su Y; Williams RO
Mol Pharm; 2020 Aug; 17(8):2789-2808. PubMed ID: 32520562
[TBL] [Abstract][Full Text] [Related]
20. Development of an Amorphous Solid Dispersion Formulation for Mitigating Mechanical Instability of Crystalline Form and Improving Bioavailability for Early Phase Clinical Studies.
Chiang CW; Lubach JW; Chen T; Chin S; Ly J; Zhang W; Hou HH; Nagapudi K
Mol Pharm; 2023 May; 20(5):2452-2464. PubMed ID: 37010134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
